Chips, Cells and Code: How Singapore is Applying its 40-Year Industrial Playbook to AI

Originally published on Medium on 19 February 2026

In the 1980s, the big bet was chips. Singapore set out to become a serious player in semiconductors and electronics, starting from low‑cost assembly and eventually becoming a key node in the global chip supply chain. In the 2000s, the spotlight shifted to cells. Biopolis and the broader biomedical sciences drive poured billions into labs, talent and cluster infrastructure to turn Singapore into “the Biopolis of Asia.”

In 2026, the new bet is code — specifically, Artificial Intelligence (AI).

Budget 2026 created a National AI Council chaired by the Prime Minister, launched “AI missions” in advanced manufacturing, connectivity, finance and healthcare, announced an expanded AI park at one‑north, committed over SGD 1 billion to a National AI R&D Plan, and introduced generous tax rebates and grants for AI adoption.

If you work in data, AI or enterprise technology in Singapore, the real question is not whether AI is a hype cycle. It’s whether this third big bet will end up looking more like the chip story, the Biopolis story, or something in between.

Act I — Chips: When the Bet Pays Off

How Singapore bet on semiconductors

In the late 1960s and 1970s, the Economic Development Board (EDB) pushed hard to attract American and Japanese electronics manufacturers. Programmes like the Electronics Industry Promotion Scheme and new industrial estates helped bring in firms such as National Semiconductor, Fairchild, Texas Instruments and HP in the late 1960s and early 1970s.

The first phase was labour‑intensive electronics assembly. But by the 1980s and 1990s, the strategy shifted up the value chain:

Wafer fabrication, through companies like Chartered Semiconductor (a joint venture involving Temasek and overseas partners).
Higher‑value components and precision engineering, supported by infrastructure in places like Jurong and supporting technical institutes.

By the late 1980s, Singapore had become the world’s largest producer of disk drives and a significant player in semiconductors.

What “success” looked like

Fast‑forward to today and the numbers are striking:

As of 2023, Singapore produces about 10% of the world’s semiconductor output and 20% of global semiconductor equipment, and 9 of the top 15 global semiconductor companies operate here.
As of 2025, semiconductor manufacturing contributes roughly 6% of Singapore’s GDP and supports more than 35,000 jobs.

This is not a side story; it is one of the core pillars of Singapore’s manufacturing base.

Hidden fragility and lessons

The chip story, however, is not a straight line up:

Chartered Semiconductor, once the world’s third‑largest contract chipmaker, struggled with losses in the 2000s and was acquired and merged into GlobalFoundries in 2009 for USD 3.9 billion.
The once‑dominant disk drive cluster has largely disappeared as technologies and global competition shifted.

Three practical lessons emerge for AI:

Compounding only happens with continuous upgrading. The chip bet paid off because Singapore kept climbing the value chain, from assembly to wafer fabs to advanced packaging and design.
Over‑reliance on a few champions is risky. When a flagship player like Chartered Semiconductor falters, you feel it.
Execution was the real advantage. Singapore’s strength lay less in inventing entirely new chip architectures and more in building the most efficient, reliable place to manufacture and move them.

Act II — Biopolis: When the Bet Is Only Half‑Won

The biomedical big bet

In 2000, Singapore launched the Biomedical Sciences Initiative. Biopolis opened in 2003 as a purpose‑built hub for biomedical research, co‑locating A*STAR institutes, public sector labs and private sector R&D. The government invested billions in infrastructure and incentives to attract big pharma, biotech firms and top researchers.

Some observers at the time described this as an attempt to create a “fourth pillar” of the economy, alongside manufacturing, finance and logistics.

Tangible successes

On paper, as of 2023, the outcomes look impressive:

Biomedical manufacturing output grew from around SGD 6 billion in 2000 to about SGD 30 billion in the early 2010s; in 2023, the biomedical cluster generated about SGD 38–40 billion in output.
In 2023, the sector accounted for roughly 2.6% of GDP and employed over 26,000 people, with biomedical manufacturing job growth outpacing overall manufacturing.
As of 2023, there are 60+ biopharma manufacturing facilities in Singapore and more than 80 leading biomedical companies with significant operations here.
A growing startup scene has taken shape: fewer than 10 biotech startups in 2012 versus about 65 in 2023, with projections for further growth.

Biopolis succeeded in making Singapore a recognised biomedical hub in Asia, with world‑class labs, manufacturing plants and a dense research community.

Where it fell short

Yet, 25 years on, even sympathetic analyses acknowledge that “the big league remains elusive.”

There are still relatively few blockbuster drugs originating from Singapore compared to the scale of investment.
A CNA long‑form article on the sector notes that Singapore is strong in discovery and manufacturing, but weaker in taking IP through late‑stage clinical development into large global products.
Graduate outcomes tell a story too: in 2023, life sciences graduates had lower median starting salaries and lower full‑time employment rates than the overall graduate average, suggesting an oversupply of generic talent relative to high‑value roles.
Philip Yeo, the former EDB chairman who drove the early push, has argued that scientists need to be more entrepreneurial and that the ecosystem needs more sophisticated, long‑horizon capital for translation.

In short: the Biopolis bet clearly improved output, jobs and capabilities, but has not yet produced a proportionate number of globally dominant biomedical companies or products.

Lessons for AI

Biopolis offers some cautionary signals for AI:

Infrastructure ≠ impact. World‑class buildings, equipment and research output do not automatically translate into commercial outcomes.
Talent must match demand. Training lots of people in a hot discipline is not enough if the downstream roles and companies don’t exist at scale.
Commercialisation paths matter. Without entrepreneurial, market‑driven translation, a sector can stall at “good jobs and publications” rather than creating globally defining firms or platforms.

Act III — AI: Singapore’s Third Big Bet

Budget 2026’s AI agenda fits squarely into this lineage.

What Budget 2026 actually does

Key elements of the AI push include:

National AI Council: A PM‑chaired council to set AI strategy, coordinate agencies and align regulation, talent and infrastructure.
AI missions in four sectors: Advanced manufacturing, connectivity/logistics, finance and healthcare — areas where Singapore already has strong clusters.
AI park at one‑north + NAIRD Plan: Expansion of the AI cluster at one‑north (the “Lorong AI” area) and a >SGD 1 billion National AI R&D Plan for 2025–2030 focused on applied and foundational AI.
And if we zoom in on enterprise incentives, we find:
- Enhanced Enterprise Innovation Scheme with a 400% tax deduction on up to SGD 50,000 of qualifying AI expenditure in YA2027 and YA2028.
- A Champions of AI programme to support end‑to‑end AI transformation (technology, process and workforce).
- An expanded Productivity Solutions Grant (PSG) list to cover more AI and AI‑enabled tools, especially for SMEs.
- Talent measures: Six months’ free access to premium AI tools for Singaporeans who enroll in selected AI‑related courses, plus redesigned AI learning pathways under SkillsFuture.

A ChannelNewsAsia commentary described this as a “shift from aspiration to execution” in AI policy.

How it rhymes with chips and Biopolis

The AI agenda clearly echoes both earlier bets:

Like chips, it focuses on sectors where Singapore already has comparative strengths: manufacturing, logistics, finance, healthcare. The goal is not to out‑research frontier labs, but to become the place where AI is deployed reliably and at scale in real industries.
Like Biopolis, it leans heavily on clusters and R&D: AI park, NAIRD funding, national missions coordinated at the centre.

The big question is which pattern will dominate.

What history suggests could go right

If the AI push follows the chips trajectory:

AI becomes deeply embedded in the operations of factories, ports, airlines, banks and hospitals, which will lift productivity in ways that persist for decades.
Singapore becomes a trusted deployment hub for AI in regulated sectors, much as it is for financial services and advanced manufacturing today.
Value‑chain upgrading continues: from basic chatbot pilots to AI‑native services, integrated data platforms, and exportable solutions.

What history suggests could go wrong

If it repeats the Biopolis pattern:

AI park and NAIRD produce high‑quality research and many pilots, but relatively few production‑grade systems at scale in the mission sectors.
Training capacity overshoots: thousands of people get “AI‑flavoured” training, but the number of genuinely applied roles in logistics, manufacturing, finance and healthcare grows more slowly.
Enterprise AI devolves into “AI theatre”: proofs‑of‑concept that look good in press releases but never make a dent in core operations or P&L.
Over‑reliance on a handful of large global vendors leads to fragile dependencies, echoing the risks of clustering around a few champions in chips or biomed.

The Budget 2026 measures are a strong start. But history suggests that execution — by enterprises and practitioners, not just the state — will determine whether this becomes another semiconductor‑level success or a Biopolis‑style half‑victory.

What This Means for Enterprises

For senior leaders in Singapore‑based enterprises, especially in finance, logistics, manufacturing and healthcare, three implications stand out.

1. Design AI programmes that look more like chips than Biopolis

Align to national missions. AI roadmaps should explicitly reference one or more of the four mission sectors. For a bank or insurer, that means focusing on AI for underwriting, claims, fraud, capital and compliance — not just generic copilots.
Take advantage of the Budget incentives. Structure projects so parts of the spend qualify for: a) EIS 400% AI deductions (up to SGD 50,000 per YA 2027–2028); b) PSG support for off‑the‑shelf tools; and c) Champions of AI transformation support where appropriate.
Invest in AI‑ready foundations. Semiconductors paid off because Singapore kept upgrading its factories and skills. For AI, that means robust data platforms, governance, MLOps and change management, not just buying tools.

2. Avoid Biopolis‑style gaps

Bake commercialisation in from day one. Treat AI initiatives as products with owners, metrics and adoption plans, not as research experiments.
Guard against talent mismatch. Be clear about the roles needed (e.g. data engineers, MLOps, applied ML in specific domains) and avoid the temptation to hire generalist “AI” talent without a roadmap for how they will be used.
Measure real impact. Use the same discipline you’d apply to a core system migration: track productivity, error rates, throughput, risk outcomes — not just “number of pilots.”

What This Means for Practitioners

For data and AI practitioners — and those trying to transition into the field — Singapore’s track record suggests a few concrete moves.

1. Pick a mission, not just a model

Singapore’s past bets have always been sector‑anchored: chips, biomed, finance, logistics. The same will be true for AI.

Rather than branding yourself as “an AI person,” it will be more powerful in Singapore’s context to become, for example:

An AI practitioner in banking/insurance,
A data/AI engineer in advanced manufacturing,
A healthcare AI specialist, or
A logistics/supply chain AI specialist.

That is where most of the Budget 2026 energy — and thus the most durable roles — are likely to be.

2. Aim for deployment, not just exposure

The signal that matters is not “I’ve taken AI courses,” but “I have deployed AI into a real workflow in a mission sector.”

Budget 2026’s offer of six months’ free access to premium AI tools with selected courses is a clear nudge: your learning journey is expected to include hands‑on work with real tools and data, not just slideware. Use that to build a portfolio of concrete projects — especially ones that map neatly to manufacturing, finance, logistics or healthcare use cases.

Closing: The Spectrum Between Chips and Biopolis

Over the last 40 years, Singapore has shown it can change its economic destiny by making a handful of big, disciplined bets.

The semiconductor bet shows what happens when that bet compounds for three decades: a major share of global output, deep local capability, and a durable economic pillar.
The Biopolis bet shows what happens when world‑class research and infrastructure are not yet matched by an equally strong commercial engine: good jobs and capabilities, but still short of the original ambition.

Budget 2026’s AI agenda is the third big bet in this sequence. It is not a passing initiative; it is the start of a multi‑decade structural shift.

The open question is where AI will land on the chips–Biopolis spectrum, and whether enterprises and practitioners treat this Budget as a prompt for serious, long‑term transformation, or just another opportunity for AI‑themed slides.